[1]Patent:WO2013/23119,2013,A1
[1]Patent:WO2013/23119,2013,A1
[1]CurrentPatentAssignee:Novartis(w/oSandoz);INCYTECORP;NOVARTISAG-WO2013/23119,2013,A1
[1]CurrentPatentAssignee:Novartis(w/oSandoz);INCYTECORP;NOVARTISAG-WO2013/23119,2013,A1Locationinpatent:Page/Pagecolumn32;33
Title: Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Journal: The Lancet. Haematology 20180201
Title: Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.
Journal: European journal of pharmacology 20151015
Title: The novel Janus kinase inhibitor ruxolitinib confers protection against carbon tetrachloride-induced hepatotoxicity via multiple mechanisms.
Journal: Chemico-biological interactions 20140905
Title: Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.
Journal: Antimicrobial agents and chemotherapy 20140401
Title: JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
Journal: Journal of immunology research 20140101
Title: Myelofibrosis: an update on current pharmacotherapy and future directions.
Journal: Expert opinion on pharmacotherapy 20130501
Title: Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors.
Journal: Arthritis and rheumatism 20121201
Title: Ruxolitinib: in the treatment of myelofibrosis.
Journal: Drugs 20121112
Title: Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
Journal: Expert opinion on pharmacotherapy 20121101
Title: Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Journal: Blood 20121025
Title: Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.
Journal: Journal of the American Academy of Dermatology 20121001
Title: Role of additional novel therapies in myeloproliferative neoplasms.
Journal: Hematology/oncology clinics of North America 20121001
Title: Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Journal: Molecular diagnosis & therapy 20121001
Title: Advances in the management of myelofibrosis.
Journal: Cancer control : journal of the Moffitt Cancer Center 20121001
Title: [Novel therapeutic options in the treatment of BCR/ABL-negative myeloproliferative neoplasms].
Journal: Deutsche medizinische Wochenschrift (1946) 20121001
Title: Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.
Journal: Blood 20120927
Title: Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback.
Journal: Journal of immunology (Baltimore, Md. : 1950) 20120915
Title: Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.
Journal: Blood 20120816
Title: Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
Journal: Blood 20120809
Title: How I treat polycythemia vera.
Journal: Blood 20120712
Title: Ruxolitinib for myelofibrosis therapy: current context, pros and cons.
Journal: Leukemia 20120701
Title: U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120615
Title: The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
Journal: Journal of clinical pharmacology 20120601
Title: Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120601
Title: Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Journal: Blood 20120517
Title: Ruxolitinib (Jakafi) for myelofibrosis.
Journal: The Medical letter on drugs and therapeutics 20120402
Title: Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.
Journal: Leukemia 20120401
Title: Breakthroughs in myeloproliferative neoplasms.
Journal: Hematology (Amsterdam, Netherlands) 20120401
Title: JAK2 inhibitors and their impact in myeloproliferative neoplasms.
Journal: Hematology (Amsterdam, Netherlands) 20120401
Title: JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths.
Journal: Blood 20120322
Title: New generation small-molecule inhibitors in myeloproliferative neoplasms.
Journal: Current opinion in hematology 20120301
Title: Management of myeloproliferative neoplasms: from academic guidelines to clinical practice.
Journal: Current hematologic malignancy reports 20120301
Title: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Journal: The New England journal of medicine 20120301
Title: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Journal: The New England journal of medicine 20120301
Title: Ruxolitinib.
Journal: Nature reviews. Drug discovery 20120201
Title: Ruxolitinib: the first agent approved for myelofibrosis.
Journal: Clinical advances in hematology & oncology : H&O 20120201
Title: Incyte comes of age with JAK inhibitor approval.
Journal: Nature biotechnology 20120109
Title: STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.
Journal: PloS one 20120101
Title: Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.
Journal: Mayo Clinic proceedings 20111201
Title: Ruxolitinib for the treatment of myelofibrosis.
Journal: Drugs of today (Barcelona, Spain : 1998) 20111101
Title: Long-term outcome of treatment with ruxolitinib in myelofibrosis.
Journal: The New England journal of medicine 20111013
Title: Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Journal: Future oncology (London, England) 20110901
Title: A potential role of ruxolitinib in leukemia.
Journal: Expert opinion on investigational drugs 20110801
Title: Targeting myeloproliferative neoplasms with JAK inhibitors.
Journal: Current opinion in hematology 20110301
Title: JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
Journal: Leukemia 20110201
Title: JAK inhibition in myelofibrosis.
Journal: The New England journal of medicine 20101216
Title: Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20101101
Title: Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
Journal: IDrugs : the investigational drugs journal 20100601
Title: Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Journal: Blood 20100415
Title: Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction.
Journal: Organic letters 20090507
Title: Novel strategies for patients with chronic myeloproliferative disorders.
Journal: Current opinion in hematology 20090301
Title: Therapeutic potential of JAK2 inhibitors.
Journal: Hematology. American Society of Hematology. Education Program 20090101
Title: Wayne Rothbaum. Methods of treating myeloproliferative neoplasms. WO2019224803A2.
